AlzeCure Pharma AB (FRA:AC6) ROE % Adjusted to Book Value: -33.69% (As of Mar. 2026)


FRA:AC6 AlzeCure Pharma AB FRA:AC6
33 GF Score
Price €0.53
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB ROE % Adjusted to Book Value?

AlzeCure Pharma AB FRA:AC6 -6.97% 33 ROE % Adjusted to Book Value is -33.69% as of Mar. 2026. GuruFocus rates FRA:AC6 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

AlzeCure Pharma AB's ROE % for the quarter that ended in Mar. 2026 was -396.16%. AlzeCure Pharma AB's PB Ratio for the quarter that ended in Mar. 2026 was 11.76. AlzeCure Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -33.69%.

AlzeCure Pharma AB ROE % Adjusted to Book Value Related Terms

AlzeCure Pharma AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB ROE % Adjusted to Book Value Chart

AlzeCure Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -14.97 -33.27 -10.97 -56.20 -29.93

AlzeCure Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.94 -9.33 -29.68 -30.90 -33.69

FRA:AC6 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, AlzeCure Pharma AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AlzeCure Pharma AB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where AlzeCure Pharma AB's ROE % Adjusted to Book Value falls into.


FRA:AC6
33GF Score
AlzeCure Pharma AB FRA:AC6
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB ROE % Adjusted to Book Value Calculation

AlzeCure Pharma AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-165.50% / 5.53
=-29.93%

AlzeCure Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-396.16% / 11.76
=-33.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -33.69% mean?
AlzeCure Pharma AB (FRA:AC6) has a ROE % Adjusted to Book Value of -33.69% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on AlzeCure Pharma AB and its competitors.
Is AlzeCure Pharma AB's ROE % Adjusted to Book Value too high?
AlzeCure Pharma AB's current ROE % Adjusted to Book Value is -33.69%. Overall, AlzeCure Pharma AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
AlzeCure Pharma AB's ROE % Adjusted to Book Value of -33.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on AlzeCure Pharma AB and its competitors. AlzeCure Pharma AB's current ROE % Adjusted to Book Value is -33.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current ROE % Adjusted to Book Value of -33.69%. The current ROE % Adjusted to Book Value is -33.69%. AlzeCure Pharma AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current ROE % Adjusted to Book Value is -33.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score

Get the complete analysis for FRA:AC6

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price